Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XTLB
stocks logo

XTLB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2016Q4
--
--
0.000
-100%
Estimates Revision
Stock Price
Go Down
down Image
-22.03%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for X T L Biopharmaceuticals Ltd (XTLB.O) is 1.75, compared to its 5-year average forward P/E of 6.77. For a more detailed relative valuation and DCF analysis to assess X T L Biopharmaceuticals Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
6.77
Current PE
1.75
Overvalued PE
14.29
Undervalued PE
-0.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
0.06
Current PS
0.02
Overvalued PS
0.12
Undervalued PS
0.01
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XTLB News & Events

Events Timeline

(ET)
2025-04-07
09:16:32
XTL Biopharmaceuticals appoints Noam Band as CEO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-01Benzinga
Vision Marine Technologies Stock Rises Over 10%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Vision Marine Technologies Performance: Vision Marine Technologies Inc. shares rose 10.5% to $1.36 in pre-market trading after announcing strong financial results for the fiscal year ending August 31, 2025, and highlighting strategic expansion following the acquisition of Nautical Ventures, which generated $12.8 million in revenue.

  • Other Gainers in Pre-Market Trading: Several stocks saw significant gains in pre-market trading, including WEBUY Global Ltd. (+62.1%), Direct Digital Holdings, Inc. (+60.6%), and INVO Fertility, Inc. (+24.7%), with various companies announcing acquisitions or strategic plans.

  • Notable Losers in Pre-Market Trading: SMX (Security Matters) PLC experienced a sharp decline of 24.6% after a previous surge, while Springview Holdings Ltd. fell 20.7% following a reverse share split announcement.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like New Fortress Energy Inc. and Canadian Solar Inc. also reporting notable increases.

[object Object]
Preview
2.0
10-08TipRanks
What’s Driving the Rise of Pharmaceutical Stocks XBIO, UPC, XTLB, and ACXP Today?

  • Pharmaceutical Stock Movements: Several pharmaceutical stocks, including Xenetic Biosciences, Universe Pharmaceuticals, XTL Biopharmaceuticals, and Acurx Pharmaceuticals, saw significant pre-market gains despite no clear news or announcements explaining the rise.

  • Speculative Trading Influence: The surge in these stocks may be linked to speculative trading following a massive rally in Galecto shares, which spiked without news and then fell, indicating that retail traders are shifting their focus to other stocks for potential gains.

[object Object]
Preview
9.0
07-07Benzinga
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket

  • Apogee Therapeutics Surge: Apogee Therapeutics, Inc. shares rose 50% to $71.19 in pre-market trading following positive results from its Phase 2 APEX clinical trial for APG777, an anti-IL-13 antibody for atopic dermatitis.

  • Market Movements: Other notable pre-market stock movements included Mullen Automotive surging 80.2% after accepting cryptocurrency for EV purchases, while BitMine Immersion Technologies fell 19.3% after a significant previous gain.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is X T L Biopharmaceuticals Ltd (XTLB) stock price today?

The current price of XTLB is 0.8733 USD — it has increased 3.93 % in the last trading day.

arrow icon

What is X T L Biopharmaceuticals Ltd (XTLB)'s business?

X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

arrow icon

What is the price predicton of XTLB Stock?

Wall Street analysts forecast XTLB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTLB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is X T L Biopharmaceuticals Ltd (XTLB)'s revenue for the last quarter?

X T L Biopharmaceuticals Ltd revenue for the last quarter amounts to 289.00K USD, decreased % YoY.

arrow icon

What is X T L Biopharmaceuticals Ltd (XTLB)'s earnings per share (EPS) for the last quarter?

X T L Biopharmaceuticals Ltd. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for X T L Biopharmaceuticals Ltd (XTLB)'s fundamentals?

The market is revising No Change the revenue expectations for XTLB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -22.03%.
arrow icon

How many employees does X T L Biopharmaceuticals Ltd (XTLB). have?

X T L Biopharmaceuticals Ltd (XTLB) has 4 emplpoyees as of December 05 2025.

arrow icon

What is X T L Biopharmaceuticals Ltd (XTLB) market cap?

Today XTLB has the market capitalization of 7.70M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free